Osteoprotegerin gene polymorphism and therapeutic response to alendronate in postmenopausal women with osteoporosis

National Medical Journal of China

Volumn 89, Issue 42, 2009, Pages 2958-2962

  Wang, Chun ^a   He, Jin Wei ^a   Qin, Yue Juan ^a   Zhang, Hao ^a   Hu, Wei Wei ^a   Liu, Yu Juan ^a   Zhang, Zhen Lin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Alendronate; Bone mineral density; Genes; Osteoporosis, postmenopausal

Indexed keywords

ALENDRONIC ACID; OSTEOPROTEGERIN;

AGED; ALLELE; ARTICLE; BONE DENSITY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; METABOLISM; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS;

AGED; ALENDRONATE; ALLELES; BONE DENSITY; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; POLYMORPHISM, GENETIC;

EID: 84871419516     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.42.004     Document Type: Article

References (15)

1. Richards JB, Rivadeneira F, Inouye M, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet, 2008, 371: 1505-1512.
2. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med, 2008, 358: 2355-2365.
3. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA, 1998, 280: 2077-2082.
4. Zhang ZL, He JW, Qin YJ, et al. Association between myostatin gene polymorphisms and peak BMD variation in Chinese nuclear families. Osteoporos Int, 2008, 19: 39-47.
5. Langdahl BL, Carstens M, Stenkjaer L, et al. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J Bone Miner Res, 2002, 17: 1245-1255.
6. Quandt SA, Thompson DE, Schneider DL, et al. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to-2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc, 2005, 80: 343-349.
7. Colon-Emeric CS. Ten vs five years of bisphosphonate treatment for postmenopausal osteoporosis: enough of a good thing. JAMA, 2006, 296: 2968-2969.
8. Nguyen TV, Center JR, Eisman JA. Pharmacogenetics of osteoporosis and the prospect of individualized prognosis and individualized therapy. Curr Opin Endocrinol Diabetes Obes, 2008, 15: 481-488.
9. 2006, 86: 361-362.
10. Zhang ZL, HJ, Qin YJ, et al. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis. Chin J Med Genet, 2003, 23: 129-133.
11. Dobnig H, Hofbauer LC, Viereck V, et al. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int, 2006, 17: 693-703.
12. 2006, 10: 204-207.
13. Kim JG, Kim JH, Kim JY, et al. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause, 2007, 14: 913-918.
14. Ueland T, Bollerslev J, Wilson SG, et al. No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women. Bone, 2007, 40: 175-181.
15. 2004, 84: 274-277.